MARKET

IMUC

IMUC

EOM Pharmaceutical Holdings Inc
OTCPK
0.210
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
0.155
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.940
52 WEEK LOW
0.121
MARKET CAP
23.79M
P/E (TTM)
-5.6150
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMUC last week (0513-0517)?
Weekly Report · 20h ago
Weekly Report: what happened at IMUC last week (0506-0510)?
Weekly Report · 05/13 11:14
Weekly Report: what happened at IMUC last week (0429-0503)?
Weekly Report · 05/06 11:21
Weekly Report: what happened at IMUC last week (0422-0426)?
Weekly Report · 04/29 11:29
Weekly Report: what happened at IMUC last week (0415-0419)?
Weekly Report · 04/22 11:17
Weekly Report: what happened at IMUC last week (0408-0412)?
Weekly Report · 04/15 11:08
Weekly Report: what happened at IMUC last week (0401-0405)?
Weekly Report · 04/08 11:13
Weekly Report: what happened at IMUC last week (0325-0329)?
Weekly Report · 04/01 11:11
More
About IMUC
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Webull offers ImmunoCellular Therapeutics Ltd stock information, including OTCPK: IMUC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUC stock methods without spending real money on the virtual paper trading platform.